Vilobelimab (anti-Complement C5) (C09-1612-298)

Vilobelimab (anti-Complement C5) is a monoclonal anti-C5a antibody to the allergen C5a, a pro-inflammatory complement division product that plays a central role in mediating organ dysfunction. Vilobelimab (anti-Complement C5) acts as a C5a inhibitor, inhibiting neutrophil activation, chemotaxis, and reducing inflammatory signalling, and may be used in studies related to sepsis, COVID-19, etc.Purity≥95% (SDS-PAGE&SEC)Endotoxin Level≤1.0EU/mgProtein FunctionActivation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled.Derived from proteolytic degradation of complement C5, C5 anaphylatoxin is a mediator of local inflammatory process. It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes. C5a also stimulates the locomotion of polymorphonuclear leukocytes (chemokinesis) and direct their migration toward sites of inflammation (chemotaxis). Specification: Recombinant, Carrier Free, ExactAb™, Azide Free, Low Endotoxin, Validated, ≥95%(SDS-PAGE&SEC), Lot by Lot